Phase 2 Trial and Open-Label Extension Top-Line Results: Once-Weekly Canvuparatide in Adults with Hypoparathyroidism September 22, 2025 Disclaimer This presentation includes forward looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our product candidates, preclinical study and/or clinical trial timelines, including projected data announcements, future results of operations and financial position, strategy and plans, in ...

Core Insights - Ascendis Pharma announced positive long-term data from the Phase 3 PaTHway Trial for TransCon PTH, showing sustained efficacy in treating adults with hypoparathyroidism [1][4] - The trial demonstrated significant improvements in biochemical markers, kidney function, and quality of life for patients [1][3] Group 1: Trial Details - The PaTHway Trial was a Phase 3, randomized, double-blind, placebo-controlled study involving 82 adults with chronic hypoparathyroidism, followed by an open-label extension [2] - At Week 156, 88% of patients had normal serum calcium levels, and 96% were independent from conventional therapy [3] - The trial maintained high retention rates, with 89% of participants completing the 3.5-year study [2] Group 2: Efficacy and Safety - Mean estimated glomerular filtration rate (eGFR) increased by 8.76 mL/min/1.73 m² across all participants, with a notable increase of 13.98 mL/min/1.73 m² in those with baseline eGFR < 60 [3] - Patients reported continued improvements in hypoparathyroidism-related symptoms and health-related quality of life, with normalization of 24-hour urine calcium excretion [3] - TransCon PTH treatment was well-tolerated, with no new safety signals identified and most treatment-emergent adverse events being mild or moderate [3] Group 3: Company Overview - Ascendis Pharma is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform [6] - The company aims to address unmet medical needs and improve patient outcomes through its product innovations [6]